Tandem Diabetes Care, Inc. (TNDM) is well-poised for growth in the coming quarters, backed by its impressive lineup of new products. The flourishing diabetes market provides a favorable opportunity for the company's growth. Strong solvency appears highly encouraging. However, concerns loom over Tandem Diabetes' substantial reliance on insulin pumps and the impact of macroeconomic challenges. In the past year, this Zacks Rank #3 (Hold) stock has surged 110.9% compared with the 6.1% growth of the industry and ...